Drug Trial Radar · NCT02183220
Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache
Last checked: Nov 19, 2026Latest source record: Jul 8, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
417
Actual
Start
Oct 1998
Primary completion
Jul 1999
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- Jul 8, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the study was to evaluate the efficacy, safety and tolerability of a single peroral dose of 0.5 g and 1.0 g metamizol relative to placebo and 1.0 g acetylsalicylic acid in 2 episodes of moderate tension headache.
Conditions
- Migraine Disorders
Interventions
MetamizolDrug
Acetylsalicylic acid (ASA)Drug
Metamizol placeboDrug
ASA placeboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time-interval weighted sum of pain intensity difference (SPID) on a Visual Analogue Scale (VAS)Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.